Contact:
4008465777
Date：2021-04-22
Author：东宝
Views：167
Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. (Dongbao Zixing), a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. (the “Company”) received the acceptance notification (No. CXHL2101065 Guo, CXHL2101066 Guo, and CXHL2101067 Guo) from the National Medical Products Administration (NMPA) on the clinical trial application for its triple-target inhibitor (THDBH101 Capsules/WXSHC071 Capsules) the other day.
The triple-target inhibitor is a Class 1 new drug, and the indication proposed in this application is type 2 diabetes. Given the multiple mechanisms of action, the product boasts a greater glucose-lowering effect than other similar medicines, and can protect cardiac, renal, and vascular systems.
The existing combo medications include Steglujan, a combination of ertugliflozin (an SGLT2 inhibitor) and sitagliptin (a DPP-4 inhibitor) jointly developed by Pfizer and Merck Sharp & Dohme, and Sogliptin, a dual SGLT1 and SGLT2 inhibitor developed by Lexicon. Neither of them is available in China.
This year has witnessed a series of moves of the Company, from the establishment of a novel drug R&D center in Hangzhou, a strategic cooperation memorandum on three novel drug projects with WuXi AppTec, to the NMPA acceptance of the clinical trial application for its triple-target inhibitor. All of these embody the Company’s philosophy of "Establishing a Global Brand Through Consistent Innovation" and its commitment to technological innovation. Going forward, the Company will make ongoing efforts to honor its commitment to being an explorer and leader of novel drugs R&D in the field of endocrinology.
